PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd to evaluate the delivery of N,N-Dimethyltryptamine (DMT) using PharmaTher’s novel microneedle patch delivery technology.
PharmaDrug said the microneedle patch delivery technology is based on novel biocompatible and biodegradable gelatin methacryloyl (GelMA) material to deliver water-soluble and insoluble drugs with desirable release profiles safely.
The GelMA-based microneedle patch can efficiently penetrate the stratum corneum layer, the outer layer of the skin, to enable flexible drug load capacity and combinations, and control-release delivery, PharmaDrug noted.
READ: PharmaDrug unveils plans for first-in-human clinical study with its lead drug candidate PD-001 in esophageal cancer
PharmaTher has completed a non-clinical research study with the Terasaki Institute for Biomedical Innovation evaluating the delivery of its DMT microneedle patch, the results of which will be available in early 2Q 2023.
Based on the results, PharmaDrug said it and PharmaTher will finalize a product and clinical development plan to initiate regulatory discussions for future clinical studies in various indications where DMT may have promise, such as major depressive disorder.
"We are excited to commence a collaboration with PharmaTher, a leader in microneedle patch delivery of psychedelics,” PharmaDrug CEO Daniel Cohen commented.
“We believe our combined programs and expertise in drug delivery and pharmacology, specifically relating to DMT, set the stage for the potential development of new treatment options for mental health conditions."
PharmaDrug is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie